Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
REDWOOD CITY, Calif., May 02, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2017 financial results after market close on Tuesday, May 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 14067412 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 14067412 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
CONTACTS:
Investors
LHA
Jody Cain, 310 691 7100
[email protected]
